Bristol-Myers Squibb and Gilead Sciences have made an agreement to commercialize their combo-drug Atripla in Canada for the treatment of HIV-1 infection in adults, subject to the approval of the product by Health Canada. Atripla is the first once-daily single tablet regimen (STR) for HIV intended as a stand-alone therapy or in combination with other antiretrovirals. It received approval from the U.S. FDA on July 12, 2006. The agreement is the result of negotiations between BMS and Gilead and ...